Molina Healthcare Aimovig Prior Authorization: A Klivira Guide

Navigating Molina Healthcare Aimovig prior authorization requires precise attention to state-specific policies and submission channels. Klivira automates this complex process, ensuring accurate and timely submissions.

For revenue cycle directors and prior authorization coordinators, managing specialty drug PAs, especially for CGRP inhibitors like Aimovig, presents significant challenges. Molina Healthcare, with its diverse Medicaid managed-care, D-SNP, and ACA marketplace plans, introduces additional layers of state-specific requirements. Understanding these nuances is critical for reducing denials and accelerating patient access to essential preventive migraine therapies.

Understanding Aimovig (Erenumab) for Migraine Prevention

Aimovig (erenumab) is a CGRP receptor antagonist indicated for the preventive treatment of both chronic and episodic migraine. As a targeted biologic, it often requires prior authorization to ensure medical necessity and adherence to payer-specific criteria. Given its role as a preventive therapy, payers like Molina Healthcare typically evaluate Aimovig within a step-therapy framework, often requiring trials of generic alternatives.

Navigating Molina Healthcare Aimovig Prior Authorization Channels

Molina Healthcare's prior authorization submission channels vary significantly by line of business and state. Medical benefit PA for Medicaid managed-care lines often routes through state-specific provider portals, similar to those for Molina California or Molina Texas. For pharmacy benefit PA, Molina's PBM relationships are state-specific, commonly utilizing ePA platforms like CoverMyMeds or Surescripts. Klivira's platform accounts for these varied submission pathways, including Availity for certain medical PA submissions, to ensure the correct form and channel are used.

Molina Healthcare Utilization Management Policies for CGRP Inhibitors

Molina Healthcare publishes its utilization management (UM) criteria through state-specific provider sites, accessible via the molinahealthcare.com providers landing page. For Aimovig (erenumab), providers must consult the precise state-specific policy to understand formulary placement, step therapy requirements, quantity limits, and specific medical necessity criteria. These policies form the basis for prior authorization decisions across Molina's Medicaid, D-SNP, and Marketplace plans.

Key Considerations for Aimovig PA Submissions to Molina Healthcare

Successful Aimovig prior authorization with Molina Healthcare hinges on comprehensive documentation. This typically includes diagnosis codes, patient history, imaging results, and a clear record of previously failed preventive migraine therapies. Common requirements include a documented trial and failure of multiple oral preventive medications. Klivira's system helps ensure all required clinical documentation is assembled and attached, reducing the likelihood of incomplete submissions.

Streamlining Aimovig Prior Authorization with Klivira and Molina Healthcare

Klivira's integration with Molina Healthcare is designed for state-aware routing, mirroring the complexity of Molina's operations across various state Medicaid agencies and managed care contracts. Our platform applies the correct decision-timeframe expectations per line of business, informed by state Medicaid mandates and CMS-0057-F applicability. This ensures that your prior authorization processes for Aimovig are compliant and efficient, from initial submission to status tracking.

Frequently asked questions

What are the common submission channels for Aimovig PA to Molina Healthcare?

Aimovig PA submissions to Molina Healthcare vary by benefit and state. Medical benefit PAs for Medicaid managed-care plans are typically submitted through state-specific provider portals or Availity. Pharmacy benefit PAs often go through ePA platforms like CoverMyMeds or Surescripts, depending on Molina's state-specific PBM relationships.

Where can I find Molina Healthcare's specific UM criteria for Aimovig (erenumab)?

Molina Healthcare's utilization management criteria for Aimovig are published on their state-specific provider websites, accessible via the main molinahealthcare.com providers landing page. It is crucial to consult the policy specific to the patient's state and Molina plan (e.g., Medicaid, D-SNP, Marketplace) for accurate requirements.

Does Molina Healthcare have step therapy requirements for Aimovig?

Yes, as a CGRP receptor antagonist for preventive migraine therapy, Aimovig typically falls under step therapy protocols with Molina Healthcare. This often requires documentation of prior trials and failures of specific generic or preferred oral preventive migraine medications before Aimovig is authorized. Specific requirements are detailed in the state-specific UM policies.

How does Klivira handle the state-specific variations for Molina Healthcare Aimovig prior authorization?

Klivira's platform provides state-aware routing and policy application for Molina Healthcare prior authorizations. Our system identifies the correct submission channel and leverages the applicable state Medicaid agency rules and Molina's UM operations, ensuring that the PA request for Aimovig is aligned with the specific requirements of the patient's plan and location.

Are Molina Healthcare's PA turnaround times impacted by CMS-0057-F?

Yes, Molina Healthcare's Medicaid managed-care, D-SNP MA, CHIP, and QHP-on-FFM lines are all impacted payers under CMS-0057-F. This rule mandates specific decision-timeframe expectations for prior authorizations. Klivira's integration applies these regulatory requirements to ensure compliance and proper tracking of PA status for Aimovig and other medications.

Related coverage

Other aimovig prior authorization by payer

Other aimovig prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo